The Effectiveness of 18F-fluorocholine PET in Detecting, Staging and Following-up Prostate Cancer
试验速览
- 阶段
- 不适用
- 入组人数
- 150
- 试验地点
- 1
研究概览
简要总结
Choline is one of the components of phosphatidylcholine, an essential element of phospholipids in the cell membrane. Some malignant cells show their ability to actively incorporate choline to produce phosphocholine and phosphatidylcholine to facilitate tumor cell duplication. The efficacy of 18F-fluorocholine (18F-FCH) for localizing primary or metastatic prostate cancer has been recently reported in limited studies. This study will be conducted to delineate the effectiveness of 18F-FCH PET in (1) differentiating benign prostate hypertrophy (BPH) from prostate cancer, (2) staging prostate cancer, (3) following-up patients with prostate cancer after initial curative therapy.
详细描述
Background:
Prostate cancer is a leading cause of cancer death for male in Taiwan. Although 18F-FDG PET has been shown to be an effective tool in diagnosing many malignancies, previous studies have shown that 18F-FDG is not a suitable PET tracer for detecting prostate cancer. Choline is one of the components of phosphatidylcholine, an essential element of phospholipids in the cell membrane. Some malignant cells show their ability to actively incorporate choline to produce phosphocholine and phosphatidylcholine to facilitate tumor cell duplication. The efficacy of 18F-fluorocholine (18F-FCH) for localizing primary or metastatic prostate cancer has been recently reported in limited studies.
Purpose:
This study will be conducted to delineate the effectiveness of 18F-FCH PET in (1) differentiating benign prostate hypertrophy (BPH) from prostate cancer, (2) staging prostate cancer, (3) following-up patients with prostate cancer after initial curative therapy.
Patients and Methods:
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 35 Years 至 90 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Group 1: 50 patients with BPH
- •Age above 35 years old
- •Histologically confirmed BPH
- •Informed consent signed
- •Group 2: 50 patients with newly diagnosed prostate cancer and
- •Age above 35 years old
- •Histologically confirmed prostate cancer
- •Informed consent signed
- •Group 3: 50 patients who have
- •Age above 35 years old
- •Histologically confirmed prostate cancer and had received curative treatment for prostate cancer
- •suspicious of recurrence/metastases because of a persistent increase in their serum PSA
- •Informed consent signed
排除标准
- •Patients with other known malignancies will be excluded.